As of the close of business on February 10, 2012, approximately 4,260,705 shares remained subject to guaranteed delivery methods. Today, Bristol-Myers Squibb obtained all the remaining outstanding shares of Inhibitex common share through a short type merger in which all such shares had been converted into the right to receive $26.00 per share, in cash and without curiosity, less any applicable withholding taxes. Bristol-Myers Squibb intends to delist and de-register Inhibitex common stock as promptly as practicable following the effective time of the merger.. Bristol-Myers Squibb acquires Inhibitex Bristol-Myers Squibb Organization announced today the successful completion of the tender present by Bristol-Myers Squibb Firm for all the outstanding shares of common share of Inhibitex, Inc.The revised main endpoint was progression-free of charge survival and just the 605 pemetrexed-treated sufferers were included in the primary evaluation, 301 of whom received cetuximab also. Median PFS was 2.9 months with pemetrexed plus cetuximab versus 2.8 months with pemetrexed, a nonsignificant difference with a hazard ratio of 1 1.03. Serious adverse events were even more regular with combination therapy than with pemetrexed only significantly; 41 percent and 29 percent of patients, respectively, experienced at least one such event. The most typical grade 3 or 4 4 adverse events with mixture therapy were exhaustion , acneiform rash , dyspnea , and decreased neutrophil count ; and with pemetrexed by itself were dyspnea , reduced neutrophil count , and fatigue .